Terms: = Sarcomas AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C
62 results:
1. Phase separation of shp2E76K promotes malignant transformation of mesenchymal stem cells by activating mitochondrial complexes.
Kan C; Tan Z; Liu L; Liu B; Zhan L; Zhu J; Li X; Lin K; Liu J; Liu Y; Yang F; Wong M; Wang S; Zheng H
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38451719
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract] [Full Text] [Related]
3. Re-expression of epigenetically silenced PTPRR by histone acetylation sensitizes RAS-mutant lung adenocarcinoma to shp2 inhibition.
Du T; Hu X; Hou Z; Wang W; You S; Wang M; Ji M; Xue N; Chen X
Cell Mol Life Sci; 2024 Jan; 81(1):64. PubMed ID: 38280930
[TBL] [Abstract] [Full Text] [Related]
4. Unveiling the role of KRAS in tumor immune microenvironment.
Xu M; Zhao X; Wen T; Qu X
Biomed Pharmacother; 2024 Feb; 171():116058. PubMed ID: 38171240
[TBL] [Abstract] [Full Text] [Related]
5. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y; Liu QP; Xie H; Ding J
Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
[TBL] [Abstract] [Full Text] [Related]
6. CDK4/6 inhibition enhances shp2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.
Wang J; Calizo A; Zhang L; Pino JC; Lyu Y; Pollard K; Zhang X; Larsson AT; Conniff E; Llosa NJ; Wood DK; Largaespada DA; Moody SE; Gosline SJ; Hirbe AC; Pratilas CA
Sci Adv; 2023 Nov; 9(47):eadg8876. PubMed ID: 38000020
[TBL] [Abstract] [Full Text] [Related]
7. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based shp2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract] [Full Text] [Related]
8. Myeloid sarcoma with
Ramia de Cap M; Wu LP; Hirt C; Pihan GA; Patel SS; Tam W; Bueso-Ramos CE; Kanagal-Shamanna R; Raess PW; Siddon A; Narayanan D; Morgan EA; Pinkus GS; Mason EF; Hsi ED; Rogers HJ; Toth L; Foucar K; Hurwitz SN; Bagg A; Rets A; George TI; Orazi A; Arber DA; Hasserjian RP; Weinberg OK;
Leuk Lymphoma; 2023 May; 64(5):972-980. PubMed ID: 36960680
[TBL] [Abstract] [Full Text] [Related]
9. Selumetinib for Refractory Pulmonary and Gastrointestinal Bleeding in Noonan Syndrome.
Chakraborty A; Beasley G; Martinez H; Jesudas R; Anton-Martin P; Christakopoulos G; Kramer J
Pediatrics; 2022 Oct; 150(4):. PubMed ID: 36082608
[TBL] [Abstract] [Full Text] [Related]
10. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.
Eckardt JN; Stölzel F; Kunadt D; Röllig C; Stasik S; Wagenführ L; Jöhrens K; Kuithan F; Krämer A; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Herbst R; Hänel M; Hanoun M; Kaiser U; Kaufmann M; Rácil Z; Mayer J; Kroschinsky F; Berdel WE; Ehninger G; Serve H; Müller-Tidow C; Platzbecker U; Baldus CD; Schetelig J; Bornhäuser M; Thiede C; Middeke JM
J Hematol Oncol; 2022 May; 15(1):60. PubMed ID: 35562747
[TBL] [Abstract] [Full Text] [Related]
11. Hexachlorophene, a selective shp2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract] [Full Text] [Related]
12. Osteosarcoma cell proliferation suppression via shp-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A.
Zhu D; Chen C; Liu X; Wang S; Zhu J; Zhang H; Kong L; Luo J
J Adv Res; 2021 Dec; 34():79-91. PubMed ID: 35024182
[TBL] [Abstract] [Full Text] [Related]
13. Discovery of 6-[(3
Czako B; Sun Y; McAfoos T; Cross JB; Leonard PG; Burke JP; Carroll CL; Feng N; Harris AL; Jiang Y; Kang Z; Kovacs JJ; Mandal P; Meyers BA; Mseeh F; Parker CA; Yu SS; Williams CC; Wu Q; Di Francesco ME; Draetta G; Heffernan T; Marszalek JR; Kohl NE; Jones P
J Med Chem; 2021 Oct; 64(20):15141-15169. PubMed ID: 34643390
[TBL] [Abstract] [Full Text] [Related]
14. High shp2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
[TBL] [Abstract] [Full Text] [Related]
15. Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.
Kawashima I; Oishi N; Kasai K; Inoue T; Hosokawa E; Nakadate A; Matsuura M; Kumagai T; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kondo T; Kirito K
Virchows Arch; 2022 May; 480(5):1101-1105. PubMed ID: 34226971
[TBL] [Abstract] [Full Text] [Related]
16. Therapy-related Myeloid Neoplasms in Children: A Single-institute Study.
Li G; Holly T; Kelly DR; Reddy V; Mikhail FM; Carroll AJ; Kutny MA
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e109-e113. PubMed ID: 33625084
[TBL] [Abstract] [Full Text] [Related]
17. Combined SHPments: An Effective Therapeutic Strategy for MPNST.
Aplin AE; Capparelli C
Cancer Res; 2021 Jan; 81(2):266-267. PubMed ID: 33452215
[TBL] [Abstract] [Full Text] [Related]
18. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract] [Full Text] [Related]
19. Distinct clonal evolution in a case with anaplastic embryonal rhabdomyosarcoma.
Kato K; Yoshimi A; Noda A; Otani H; Hojo H; Tanaka M; Tanaka Y; Ito Y; Nishimura R; Takita J; Yanai T; Koike K; Tsuchida M
Pediatr Int; 2021 Jul; 63(7):782-789. PubMed ID: 33021000
[TBL] [Abstract] [Full Text] [Related]
20. A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Li J; Liu L; Zhang Q; Huang Y; Zhang Y; Gan X; Liu S; Yue Z; Wei Y
Medicine (Baltimore); 2020 Jun; 99(26):e20725. PubMed ID: 32590748
[TBL] [Abstract] [Full Text] [Related]
[Next]
